Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

China-based gene therapy developer Exegenesis Bio received more than $10m in funding in August this year, raising the money from investors including Legend Star, a corporate venturing vehicle for conglomerate Legend Holdings, 36Kr reported on Monday. K2VC and Kaitai Capital also participated in the round, which will fund work on the company’s drug pipeline. Gradient…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.